Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

PURPOSE: Ceftazidime–avibactam is a novel antimicrobial combining a third-generation cephalosporin with a non-β-lactam β-lactamase inhibitor that was recently approved to treat Gram-negative hospital- and ventilator-acquired pneumonia. The use of ceftazidime–avibactam to treat Pseudomonas aeruginosa...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkin, Stan D, Abid, Shadaan, Foster, Michael, Bose, Moumita, Keller, Ashley, Hollaway, Rita, Sader, Helio S, Greenberg, David E, Finklea, James D, Castanheira, Mariana, Jain, Raksha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149938/
https://www.ncbi.nlm.nih.gov/pubmed/30271183
http://dx.doi.org/10.2147/IDR.S173804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149938/
https://www.ncbi.nlm.nih.gov/pubmed/30271183
http://dx.doi.org/10.2147/IDR.S173804

Ejemplares similares